Global Esophageal Cancer Market by Type (Esophageal Adenocarcinoma, Esophageal Squamous-Cell Carcinoma), Cancer Phase (Phase I, Phases II, Phases III), Treatment, End-Users - Forecast 2024-2030

Report
195 Pages
June 2024
Region: Global
360iResearch™
ID: 5967803

The Esophageal Cancer Market grew from USD 14.90 billion in 2023 to USD 16.08 billion in 2024. It is expected to continue growing at a CAGR of 8.26%, reaching USD 25.99 billion by 2030.

The esophagus plays an important role in the digestive system, facilitating the movement of swallowed food & liquids from the mouth to the stomach for digestion. This particular cancer can occur when malignant cells form in the tissues of the esophagus, leading to the development of tumors. Esophageal cancer is known for its aggressive nature and potential to spread rapidly to nearby organs and lymph nodes, making early detection and treatment essential for improving patient outcomes. Despite advancements in diagnostic techniques and treatment methodologies, the prognosis for esophageal cancer remains challenging, underscoring the importance of ongoing research and development in this field. An increase in esophageal cancer cases worldwide significantly fuels market growth. Innovations in diagnostics and treatments, such as minimally invasive surgical techniques and novel drug therapies, have propelled the market demand forward. However, the high cost of advanced therapies can limit market growth, especially in low-income regions. Moreover, side effects associated with current treatment options may deter patient compliance. Nevertheless, new therapeutic approaches, including immunotherapy and personalized medicine, present lucrative opportunities for growth in the esophageal cancer market. Advancements in early detection and screening methods also offer substantial market potential.

Regional Insights

The Americas, particularly North America, exhibit a high level of diversity in esophageal cancer incidents, primarily influenced by lifestyle factors, including smoking and dietary habits. Treatment approaches in the region are advanced, focusing on early detection and multidisciplinary care, integrating surgery, radiation, and chemotherapy. Precision medicine is also gaining traction, especially in the U.S., where genetic profiling and targeted therapies are increasingly utilized. Moreover, the Americas is home to numerous clinical trials and research initiatives to improve diagnosis, treatment, and patient outcomes, showcasing an evolving landscape towards more personalized and effective care for esophageal cancer patients. In the EMEA region, the incidence of esophageal cancer varies significantly, with higher rates observed in Eastern Europe and certain parts of Africa. The predominant type in Eastern Europe and the Middle East is squamous cell carcinoma, attributed to tobacco use, high alcohol consumption, and dietary factors. The region benefits from well-coordinated healthcare systems, particularly in Europe, facilitating access to comprehensive care and advanced treatments, including minimally invasive surgical techniques and innovative chemotherapeutic agents. The Asia Pacific region showcases the highest incidence of esophageal cancer globally, with notable hotspots in Eastern Asia, including China. Squamous cell carcinoma is the most common type, with dietary habits, smoking, and certain environmental factors implicated in its prevalence. Treatment modalities in the region vary significantly, with advanced healthcare systems in countries such as Japan and South Korea offering cutting-edge treatment options. Conversely, rural areas and less developed countries face challenges with access to care and reliance on traditional treatment methods.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Esophageal Cancer Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing prevalence of esophageal cancer and need for timely treatment
Development of sophisticated esophageal cancer diagnostic techniques
Government initiatives and funding for cancer research

Market Restraints

Adverse recalls of esophageal cancer drugs

Market Opportunities

Advancements in esophageal cancer medications with favorable government approvals
Emergence of targeted therapies and immunotherapies

Market Challenges

Complexity in development of therapeutics

Market Segmentation Analysis

Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery

Industry Insights

Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Esophageal Cancer Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Esophageal Cancer Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma

In a pivotal development by China's National Medical Products Administration, sugemalimab (Cejemly), in conjunction with fluorouracil and platinum-based chemotherapy, has received approval for the first-line treatment of patients suffering from recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). This decision is underpinned by compelling data from the phase 3 GEMSTONE-304 study, showcasing the regimen's substantial impact on improving progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone. Furthermore, the treatment demonstrated a superior objective response rate and a longer duration of response, alongside a manageable safety profile, marking a significant advancement for those affected by advanced ESCC.

China-based biotech receives approval for esophageal cancer treatment

Henlius Biotech received approval from the National Medical Products Administration (NMPA) for a groundbreaking treatment for esophageal squamous cell carcinoma (ESCC). The treatment, HANSIZHUANG (serplulimab injection), an anti-PD-1 monoclonal antibody, is now approved for use in combination with fluorouracil and platinum-containing drugs. This combination is aimed at the first-line treatment of patients with PD-L1 positive, unresectable, locally advanced, recurrent, or metastatic ESCC, marking a significant advancement in the fight against this type of cancer.

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

Innovent Biologics, Inc. shared the compelling final analysis of the ORIENT-15 Phase 3 study on sintilimab, used with chemotherapy for first-line esophageal squamous cell carcinoma (ESCC) treatment. This study involved 690 patients, showing that the sintilimab combination markedly enhanced median overall survival by 4.6 months across all patients and by 3.9 months in PD-L1 positive patients, reducing death risk by 33.9% and 36.5%, respectively. The ORIENT-15 study marks a promising advancement in ESCC treatment, advocating sintilimab plus chemotherapy as a critical first-line therapy option.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Esophageal Cancer Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Esophageal Cancer Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co., Ltd, Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Esophageal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Esophageal Adenocarcinoma
Esophageal Squamous-Cell Carcinoma

Cancer Phase

Phase I
Phases II
Phases III

Treatment

Chemotherapy
Radiotherapy
Surgery

End-Users

Cancer Research Institutes
Diagnostic Laboratories
Hospitals & Clinics

Region

Americas

Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific

Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa

Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Additional Product Information:

The purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase
Purchase of this report includes 1 year online access with quarterly updates
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: The recorded online access option does not include the preconference workshop.

The recorded online access option does not include the pre-conference workshop.

Please note: 10% free customization equates to up to 3 hours of analyst time.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of esophageal cancer and need for timely treatment
5.1.1.2. Development of sophisticated esophageal cancer diagnostic techniques
5.1.1.3. Government initiatives and funding for cancer research
5.1.2. Restraints
5.1.2.1. Adverse recalls of esophageal cancer drugs
5.1.3. Opportunities
5.1.3.1. Advancements in esophageal cancer medications with favorable government approvals
5.1.3.2. Emergence of targeted therapies and immunotherapies
5.1.4. Challenges
5.1.4.1. Complexity in development of therapeutics
5.2. Market Segmentation Analysis
5.2.1. Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
5.2.2. Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Esophageal Cancer Market, by Type

6.1. Introduction
6.2. Esophageal Adenocarcinoma
6.3. Esophageal Squamous-Cell Carcinoma

7. Esophageal Cancer Market, by Cancer Phase

7.1. Introduction
7.2. Phase I
7.3. Phases II
7.4. Phases III

8. Esophageal Cancer Market, by Treatment

8.1. Introduction
8.2. Chemotherapy
8.3. Radiotherapy
8.4. Surgery

9. Esophageal Cancer Market, by End-Users

9.1. Introduction
9.2. Cancer Research Institutes
9.3. Diagnostic Laboratories
9.4. Hospitals & Clinics

10. Americas Esophageal Cancer Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Esophageal Cancer Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Esophageal Cancer Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma
13.3.2. China-based biotech receives approval for esophageal cancer treatment
13.3.3. Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio

List of Figures

FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
FIGURE 2. ESOPHAGEAL CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ESOPHAGEAL CANCER MARKET DYNAMICS
FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 63. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 64. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 65. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 66. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 67. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 68. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 69. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 70. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 71. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 72. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 73. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 74. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 75. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 76. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 77. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 78. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 107. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 108. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 109. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 110. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 111. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 112. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 113. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 114. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 115. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 116. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 117. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 118. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 119. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 120. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 121. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 122. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 131. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 132. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 133. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 134. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 135. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 136. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 137. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 138. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 179. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 180. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 181. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 182. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 183. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 184. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 185. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 186. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 205. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 208. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 209. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 210. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 211. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 212. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 213. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 214. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 215. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 216. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 217. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 218. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 219. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 220. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 221. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 222. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 223. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 224. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 225. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 226. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 227. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 228. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 229. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 230. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 231. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 232. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 233. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 234. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 235. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 236. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 237. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 238. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 239. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 240. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 241. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 242. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 243. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 244. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 253. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 254. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 255. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 256. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 257. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 258. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 259. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 260. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 269. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 270. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 277. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 280. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 281. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 282. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 283. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 284. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 285. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 286. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 287. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 288. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 289. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 290. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 291. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 292. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 293. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 294. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 295. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 296. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 297. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 298. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 299. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 300. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 301. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 302. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 310. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 312. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 318. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 320. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 325. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 326. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 327. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 328. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 329. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 330. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 331. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 332. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 333. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 334. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 335. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 336. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 337. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 338. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 339. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 340. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 341. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 342. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 343. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 344. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 345. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 346. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 347. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 348. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 349. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 350. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 351. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 352. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 353. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 354. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 355. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 356. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2023 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2024-2030 (USD MILLION)
TABLE 361. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 362. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 363. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 364. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 365. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 366. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 367. UNITED KINGDOM ESOPHAGEAL C

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca plc
Aurobindo Pharma Limited
Bausch Health Companies Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hikma Pharmaceuticals PLC
Jiangsu Hengrui Medicine Co., Ltd
Johnson & Johnson Private Limited
LEO Pharma A/S
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	195
Published	June 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 16.08 Billion
Forecasted Market Value ( USD ) by 2030	$ 25.99 Billion
Compound Annual Growth Rate	8.2%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF, Excel And Online Access

1 - 5 User License PDF, Excel And Online Access

Enterprise License PDF, Excel And Online Access

need a quote ?

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3651EUR$3,939USD£3,077GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€4587EUR$4,949USD£3,866GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6460EUR$6,969USD£5,444GBP